The layoffs will affect 150 long-tenured salespeople in Gilead’s cardiopulmonary division, which markets two drugs, Ranexa and Letairis, which recently lost patent exclusivity.
The decision is unfortunate but necessary to cut costs, Gilead said. The drugmaker already warned investors that sales generated by the two drugs would fall as generics enter the market.
The layoffs are effective July 1.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.